Journal of Cancer Therapy

Volume 11, Issue 5 (May 2020)

ISSN Print: 2151-1934   ISSN Online: 2151-1942

Google-based Impact Factor: 0.35  Citations  

Efficacy of Oncoxin-Viusid on the Reduction of Adverse Reactions to Chemotherapy and Radiotherapy in Patients Diagnosed with Cervical Cancer and Endometrial Adenocarcinoma

HTML  XML Download Download as PDF (Size: 326KB)  PP. 276-295  
DOI: 10.4236/jct.2020.115023    694 Downloads   2,817 Views  Citations

ABSTRACT

Introduction: Oncoxin-Viusid (OV) has shown antioxidant, immunomodulatory and anti-tumour capabilities in experimental studies on humans and animal subjects. Acute toxicity of Radiation Therapy (RT) and Chemotherapy (CT) in patients with cervical cancer and endometrial adenocarcinoma impact quality of life and, therefore, outcomes of these therapies. Objective: To identify Oncoxin-Viusid’s efficacy in reducing acute toxicity produced by onco-specific treatments in patients with cervical cancer and endometrial adenocarcinoma. Materials and Methods: A controlled, randomised double-blind phase II clinical trial was performed with a sample size of 63 patients distributed into 2 groups: one receiving the standard treatment plus the Oncoxin-Viusid nutritional supplement (OV group) and another receiving the standard treatment and placebo (P group). The primary efficacy variable is the proportion of secondary disruptions to acute adverse reactions produced by RT and CT. Results: The number of patients suffering adverse events from chemotherapy was 20.6% less in the OV group (70.0%) than in the placebo group (90.6%) (p = 0.04). We recorded consistently normal values of haemoglobin (-6.2 OV group vs -8.3 P group, p = 0.009), platelet count (-17.4 OV group vs -27.6 P group, p = 0.009) and leukocytes (-31.8 OV group vs -41.4 P group, p = 0.025) in the OV group, tolerating 4 more cytostatic doses on average than the placebo group. Significant increase in quality of life (QLQ-30) was registered in the OV group with a large effect size on such issues as emotional and social function (Cohen’s d = 0.9), as well as in the reduction of symptoms like dyspnea 60%, insomnia 15% and anorexia 30% (item CX-2), (Cohen’s d = 0.98), which were higher than the placebo group. Conclusions: OV administration reduces onco-specific adverse events and improves quality of life in patients diagnosed with cervical cancer and endometrial adenocarcinoma undergoing radiation therapy and chemotherapy.

Share and Cite:

Lorente, R. , Durán, D. , Viamontes, J. , Anta, J. , Reyes, R. and Navares, E. (2020) Efficacy of Oncoxin-Viusid on the Reduction of Adverse Reactions to Chemotherapy and Radiotherapy in Patients Diagnosed with Cervical Cancer and Endometrial Adenocarcinoma. Journal of Cancer Therapy, 11, 276-295. doi: 10.4236/jct.2020.115023.

Cited by

[1] Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer
Unzueta, A Benedicto, U Telleria, E Sanz… - Nutrients, 2023
[2] Patients with Trachelectomy Surgery Sexual Performance Domains in Cervical Cancer Patients
Journal of Obstetrics …, 2023
[3] The Administration of Ocoxin Increases the Quality of Life of Patients with Advanced Epithelial or Metastatic Ovarian Cancer Undergoing Neoadjuvant …
Journal of Cancer …, 2022
[4] СИРОП КОРНЯ СОЛОДКИ С ДОБАВКАМИ БИОЛОГИЧЕСКИ АКТИВНЫХ ВЕЩЕСТВ И СПОСОБ ПОЛУЧЕНИЯ СИРОПА НА ЭЛЕКТРОХИМИЧЕСКИ …
… технологий в медицине и …, 2021
[5] Ocoxin oral solution demonstrates antiviral properties in cellular models
2021
[6] Ocoxin as a complement to first line treatments in cancer
2021
[7] Oncoxin‑Viusid® may improve quality of life and survival in patients with hormone‑refractory prostate cancer undergoing onco‑specific treatments
2020
[8] Antitumoral Properties of the Nutritional Supplement Ocoxin Oral Solution: A Comprehensive Review
2020
[9] Биологически активные добавки. Разработка и маркетинг
Известия ГГТУ …, 2020
[10] Ocoxin osagarri naturalaren eragin antitumorala pankreako minbiziko eta kolon-ondesteko minbiziaren metastasi hepatikoko eredu esperimentaletan.
2020

Copyright © 2025 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.